Abstract
IntroductionThe use of immune-checkpoint inhibitors has drastically improved the management of patients with non-small cell lung cancer (NSCLC), but innate and acquired resistances are hurdles needed to be solved. Immunomodulatory...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have